Intravenous Immunoglobulins Market Analysis 2026

Market Dynamics of The Intravenous Immunoglobulin Market

Key Drivers for The Intravenous Immunoglobulin Market

• The rising prevalence of immunodeficiency disorders fuels the intravenous immunoglobulin market.

An increase in the incidence of immunodeficiency illness and a sharp rise in the number of immunodeficiency medicine releases by well-known companies are the main drivers propelling the market's expansion. Through the replacement of insufficient antibodies, infection prevention, enhancement of immunological function, and management of autoimmune symptoms, immunoglobulins play a critical role in the management of immunodeficiency illnesses. By replacing the absent antibodies, intravenous immunoglobulins (IVIG) help to avoid repeated infections. Due to the increasing prevalence of immunodeficiency diseases, the market is anticipated to rise rapidly throughout the projected period. 
For instance, as per the article published by BioMed Central Ltd in March 2022, the prevalence of Common Variable Immunodeficiency (CVID) in the same population was approximately 16.6% in the United States, 22.5% in Canada, and 34.2% in Australia in 2021. The high prevalence of CVID and improved diagnosis and awareness have increased the demand for immunoglobulin therapies. 
Source:(https://aacijournal.biomedcentral.com/articles/10.1186/s13223-022-00662-6)

Thus the increasing prevalence of immunodeficiency disorders is driving immunoglobulin market growth, supported by rising medication releases and the critical role of immunoglobulins in managing these disorders.
For instance, as per an April 2020 update by the Centers for Disease Control and Prevention (CDC), there are more than 400 types of primary immunodeficiencies that vary in severity. Thus, these statistics reflect the rising need for immunoglobulins for the treatment of immunodeficiency disorders.
Source:(https://www.cdc.gov/primary-immunodeficiency/about/index.html#:~:text=There%20are%20more%20than%20400,is%20found%20soon%20after%20birth.)
Thus, these statistics project the rising need for immunoglobulin for the treatment of immunodeficiency disorders through intravenous infusion driving the growth of the intravenous immunoglobulin (IVIG) market.

• The increasing prevalence of rheumatoid arthritis disease propels the growth of intravenous immunoglobulin.

The rising prevalence of rheumatoid arthritis (RA) serves as a significant driver for the growth of intravenous immunoglobulin (IVIG) therapy. RA, a chronic autoimmune disorder affecting joints, is characterized by inflammation and tissue damage, leading to pain, swelling, and impaired mobility. IVIG, with its immunomodulatory properties, offers a promising treatment avenue for RA patients who may have failed conventional therapies. Its ability to regulate immune responses and modulate inflammatory pathways makes it a valuable option, especially in cases where conventional disease-modifying anti-rheumatic drugs (DMARDs) are insufficient or contraindicated. As the prevalence of RA continues to rise globally, the demand for effective and alternative treatments like IVIG is expected to increase, thereby propelling the growth of IVIG therapy in the management of rheumatoid arthritis.
For instance, in 2023, according to the Australian Institute of Health and Welfare, rheumatoid arthritis accounted for 2.0% of total disease burden (DALY); 3.6% of non-fatal burden (YLD), and 0.1% of fatal burden (YLL). In 2020–21, an estimated $966.1 million of expenditure in the Australian health system was for rheumatoid arthritis, representing 0.6% of total health system expenditure and 6.6% of expenditure for all musculoskeletal conditions. Within the musculoskeletal conditions disease group, rheumatoid arthritis accounted for 15.7% of total burden (DALY); 15.7% of non-fatal burden (YLD); and 15.5% of fatal burden (YLL) (AIHW 2023a).
Source:(https://www.aihw.gov.au/reports/chronic-musculoskeletal-conditions/rheumatoid-arthritis)

For instance, in July 2022, according to the National Rheumatoid Arthritis Society (NRAS), a UK-based non-profit organization, it was estimated that more than 450,000 people in the UK have rheumatoid arthritis. The most common age for people to develop RA is between 40 and 60, or a bit older for men. 
Source:(https://nras.org.uk/resource/what-is-ra/)

For instance, in a 2021 investigation according to American Pharma Specialty Care, researchers observed the potent anti-inflammatory action of IVIG in mice, suggesting the potential role of IVIG for rheumatoid arthritis in humans
Source:(https://ameripharmaspecialty.com/ivig-for-rheumatoid-arthritis-does-it-really-work/)
Therefore, the increasing prevalence of rheumatoid arthritis is creating the need for immunoglobulin for treatment of rheumatoid arthritis through intravenous infusion driving the growth of the intravenous immunoglobulin (IVIG) market.

Restraint Factor for The Intravenous Immunoglobulin Market
 

• The high cost of intravenous immunoglobulin therapy and its associated side effects restrain the growth of the intravenous immunoglobulin market

Demand for intravenous immunoglobulin treatments is severely constrained by their high cost. These treatments have higher production costs because they need intricate manufacturing procedures and exacting quality standards. Because of this, it is difficult for patients, healthcare professionals, and healthcare systems to pay and obtain these necessary therapies. Intravenous immunoglobulin treatments are not widely used because of the cost aspect, especially in areas with tight healthcare budgets and resources.
Furthermore, by affecting patient trust and adherence, the possibility of side effects and unpleasant responses limits market demand. Adverse effects from intravenous immunoglobulin therapy can range in severity from minor responses to serious problems. Fears regarding safety and possible side effects would discourage doctors and patients from choosing these treatments, which would impede the intravenous immunoglobulin products' general expansion and adoption in the medical community. It is imperative to tackle these obstacles to guarantee increased accessibility and long-term market expansion.
For instance, in January 2022 patients require regular infusions, which affects their quality of life. The financial burden is also significant: The treatment costs between $30,000 and $90,000 in the U.S. Consequently, the elevated treatment expenses are expected to act as a barrier to market demand.
Source:(https://www.research.chop.edu/cornerstone-blog/is-lifelong-immunoglobulin-replacement-therapy-cost-effective-to-treat-agammaglobulinemia#:~:text=The%20therapy%20reduces%20the%20number,and%20%2490%2C000%20in%20the%20U.S.)

For instance, according to a 2023 article published by AmeriPharma Specialty Care, a single IVIG infusion can cost anywhere from $100 to over $350 or more per gram. n average, the reported cost for IVIG treatment in the US is approximately $9,720, and if patients undergo 4 to 5 infusions per month, then it would cost them around $41,796 per month. Even though IVIG infusions offer hope and an improved quality of life, the financial aspect can be daunting for many patients and their families.
Source:(https://ameripharmaspecialty.com/cost-of-ivig-treatment/)
However, the high cost and potential side effects of intravenous immunoglobulin therapy pose challenges to market demand, hindering accessibility and adoption within the medical community.

How did COVID-19 impact the Intravenous Immunoglobulin Market

The COVID-19 epidemic has had three primary effects on the economies of different parts of the world: firstly, it has directly impacted supply and demand; second, it has disrupted distribution networks; and third, it has had a financial impact on businesses and financial markets. Several nations, worldwide are having issues with the distribution and delivery of medical supplies. However, because more research and development is being done on intravenous immunoglobulins (IVIG) for the treatment of COVID-19, the impact of the coronavirus (COVID-19) pandemic is anticipated to propel the growth of the intravenous immunoglobulin market.
For instance, according to an October 2020 published article titled, 'The uSAGE of Intravenous Immunoglobulin Gamma for the treatment of severe coronavirus disease 2019: a randomized placebo-controlled double-blind clinical trial', the administration of intravenous immunoglobulin in patients with severe COVID-19 infection was expected to enhance the clinical outcome and aid in a significant reduction of the mortality rate due to SARS-CoV2 viral infection. Hence, the global market is likely to witness strong growth during the pandemic.
Source:(https://pubmed.ncbi.nlm.nih.gov/33087047/)

•    For instance, according to the article published in Respiration journal, in January 2021, early IVIG administration was associated with reduced ventilator use, hospital and intensive care unit length of stay in a retrospective study conducted in the U.S. and Germany including patients from three hospitals. In a retrospective study of 58 cases with severe or critical illness due to COVID-19, early administration of IVIG was associated with reduced ventilator use, reduced hospital and intensive care unit length of stay, and improved 28-day mortality.
Source:(https://karger.com/res/article/99/12/1087/308146/Intravenous-Immunoglobulin-for-the-Treatment-of)

Opportunities for The Intravenous Immunoglobulin Market

• Advancement in human plasma-derived IVIG products may represent a significant opportunity to drive the intravenous immunoglobulin market.

Advancements in human plasma-derived IVIG (intravenous immunoglobulin) products offer a significant opportunity to propel the intravenous immunoglobulin market forward due to several key factors. Improvements in purification processes and technology enhance product quality and safety, reducing the risk of adverse reactions and increasing patient acceptance. Innovations in manufacturing enable higher yields and more efficient production, potentially alleviating supply constraints and meeting growing demand. Additionally, refined formulations and tailored product profiles may lead to enhanced efficacy for treating a broader range of autoimmune and inflammatory conditions, expanding the market reach and utility of IVIG therapy. Moreover, these advancements position plasma-derived IVIG products as a cornerstone in the management of various chronic inflammatory diseases and immune-mediated disorders, driving market growth and improving patient outcomes.
For instance, in January 2024 OSAKA, Japan and CAMBRIDGE, Massachusetts, January 29, 2024 – Takeda announced that the U.S. Food and Drug Administration (FDA) has approved GAMMAGARD LIQUID [Immune Globulin Infusion (Human) 10% solution] as an intravenous immunoglobulin (IVIG) therapy derived from human plasma to improve neuromuscular disability and impairment in adults with chronic inflammatory demyelinating polyneuropathy (CIDP)
Source:(https://www.takeda.com/en-us/newsroom/news-releases/2024/takedas-gammagard-liquid-approved-for-adults-with-cidp-in-united-states#:~:text=OSAKA%2C%20Japan%20and%20CAMBRIDGE%2C%20Massachusetts,to%20improve%20neuromuscular%20disability%20and)

For instance, in June 2021, Octapharma, a Swiss pharmaceutical company, announced that its new product ‘Octagam 10%’, a human plasma-derived intravenous immunoglobulin (IVIg) was granted approval by the European Union (EU) as immunotherapy for adults with dermatomyositis, and national approval by Germany for the same indication. Octagam 10% is the first therapy to be approved for dermatomyositis in the EU and indicated for adults with active dermatomyositis treated with immunosuppressive drugs. This innovative product will help improve the lives of people with dermatomyositis, which is a rare, idiopathic autoimmune disorder.
Source:(https://www.octapharma.com/news/press-release/2021/approval-of-octagam-10percent-for-adults-with-dermatomyositis)
Thus, advancements in human plasma-derived IVIG products enhance safety, increase efficiency, and improve efficacy, driving market growth and expanding treatment options for chronic inflammatory immune-mediated disorders.

With the help of the above study about the Intravenous Immunoglobulin Market, it can be concluded that the market for intravenous immunoglobulin worldwide is expected to develop significantly shortly. From the report, one can understand and infer the market dynamics, segmentations, status and trends, and key players in the market. It provides data regarding various topics such as market dimensions, prevailing trends, competitive landscape, and the outlook for prospective expansion. This allows the reader to understand and access reliable data about the market and industry.

Frequently Asked Questions